The latest price target for Adial Pharmaceuticals (NASDAQ:ADIL) was reported by Rodman & Renshaw on November 14, 2024. The analyst firm set a price target for $8.00 expecting ADIL to rise to within 12 months (a possible 661.90% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Adial Pharmaceuticals (NASDAQ:ADIL) was provided by Rodman & Renshaw, and Adial Pharmaceuticals initiated their buy rating.

There is no last upgrade for Adial Pharmaceuticals

The last downgrade for Adial Pharmaceuticals Inc happened on August 17, 2022 when Maxim Group changed their price target from N/A to N/A for Adial Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a initiated with a price target of $0.00 to $8.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $1.05, which is within the analyst’s predicted range.